• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Pentasa Sachet Prolonged Release Granules
    / Ferring Pharmaceuticals


    Active Ingredient
    Mesalazine 1, 2, 4 g

    Status in Israel
    RX

    Presentation and Status in Health Basket

    Presentation Basket Yarpa Pharmasoft

    Sachets

    100 x 1 g

    partial basket chart 20492 16372

    Sachets

    60 x 2 g

    partial basket chart 89247 16785

    Sachets

    30 x 4 g

    partial basket chart 11976

    Dosage

    Ulcerative Colitis
    Adults: Active treatment: Individual dosage, up to 4 g mesalazine once daily or in two or three divided doses.
    Maintenance treatment: Recommended dosage, 2 g mesalazine once daily.
    Crohn’s Disease
    Adults: Active treatment: Individual dosage, up to 4 g mesalazine daily in two or three divided doses.
    Maintenance treatment: Individual dosage, up to 4 g mesalazine daily in two or three divided doses.
    Paediatric population
    The safety and efficacy in children below 6 years have not been established. There is only limited documentation for an effect in children (age 6-18 years)
    Ulcerative colitis
    Children 6 years of age and older: Active disease: To be determined individually, starting with 30-50 mg/kg/day in divided doses. Maximum dose: 75 mg/kg/day in divided doses. The total dose should not exceed 4 g/day (maximum adult dose).
    Maintenance treatment: To be determined individually, starting with 15-30 mg/kg/day in divided doses. The total dose should not exceed 2 g/day (recommended adult dose). It is generally recommended that half the adult dose may be given to children up to a body weight of 40 kg; and the normal adult dose to those above 40 kg.
    Crohn’s disease
    Treatment of active disease: Children 6 years of age and older: To be determined individually, starting with 30-50 mg/kg/day in divided doses. Maximum dose: 75 mg/kg/day in divided doses. The total dose should not exceed 4 g/day (maximum adult dose).
    Maintenance treatment: Children 6 years of age and older: To be determined individually, starting with 15-30 mg/kg/day in divided doses. The total dose should not exceed 4g/day (recommended adult dose).
    It is generally recommended that half the adult dose may be given to children up to a body weight of 40 kg; and the normal adult dose to those above 40 kg.
    Method of Administration: Pentasa® Tablets or Granules must not be chewed. To facilitate swallowing the tablets may be dispersed in 50ml of cold water. Stir and drink immediately. The contents of the sachet should be emptied onto the tongue and washed down with some water or juice.


    Indications

    Crohn’s disease, ulcerating colitis.

     


    Contra-Indications

    Hypersensitivity to mesalazine, any other component of the product or salicylates. Severe liver and/or renal impairment.

     


    Special Precautions

    Patients allergic to sulphasalazine (risk of allergy to salicylates).


    Side Effects

    N/A

     


    Drug interactions

    Aspirin, diphenhydramine, probenicid, isoniazide, rifamipicin.


    Manufacturer
    Ferring Pharmaceuticals
    CLOSE